Clinical Trials Decriminalization Policy Safety 
Cannabis Law Report
SEPTEMBER 23, 2022
Senate Bill 519 would have decriminalized the personal possession of certain psychedelic substances, legalized life-saving public health interventions, and studied future approaches to increasing use of psychedelics. However, the Assembly Appropriations Committee stripped the primary intention from the bill.
SpeedWeed
JULY 6, 2021
Harvard Law School is planning to open the first US policy center focused on the legalization and regulation of psychedelics like psilocybin, MDMA, and LSD. . Harvard’s new center will be the first to focus solely on psychedelics policy and laws rather than research, though. View original article.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 1, 2021
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. Here’s the press release. The Project on Psychedelics Law and Regulation (POPLAR).
Cannabis Law Report
JUNE 10, 2021
Marijuana policies in the United States have become more permissive, motivating research on demographic and policy-based differences in behaviors and attitudes towards driving after marijuana use. The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use.
Canna Law Blog
NOVEMBER 6, 2021
To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder.
NORML
JANUARY 4, 2019
Separate provisions in the bill exclude cannabidiol from the federal definition of marijuana, permit VA doctors to authorize medical cannabis access to qualified patients, and remove undue federal barriers to clinical trial research to better assess the safety and efficacy of medical cannabis. Pennsylvania.
NORML
JANUARY 28, 2019
Presidents Barack Obama and Donald Trump have voiced support for state governments deciding their own policies. The National Center for Biotechnology Information has summarized a group of FDA approved randomized clinical trials, finding evidence for cannabis as medicine. So, in seven years why hasn’t Kentucky moved forward?
Expert insights. Personalized for you.
52 
Let's personalize your content